Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
10.3971/j.issn.1000-8578.2021.20.1449
- VernacularTitle:PD-1/PD-L1免疫检查点抑制剂致心脏毒性的研究进展
- Author:
Lin YU
1
;
Guangping LI
;
Changyu ZHOU
;
Huaying FU
Author Information
1. Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
- Publication Type:Research Article
- Keywords:
PD-1/PD-L1;
Immune checkpoint inhibitors;
Cardiotoxicity;
Progress
- From:
Cancer Research on Prevention and Treatment
2021;48(8):794-798
- CountryChina
- Language:Chinese
-
Abstract:
Cardiotoxicity is a serious complication of antineoplastic drugs. With the continuous development of antineoplastic drugs, immune checkpoint inhibitors have been used in the treatment of a variety of cancers. PD-1/PD-L1 immune checkpoint inhibitors have been widely concerned in recent years. This article reviews the manifestations and possible mechanisms of cardiotoxicity induced by PD-1/PD-L1 immune checkpoint inhibitors, and the detection methods and treatment of cardiotoxicity.
